GlassScriptPhysician profile
Reshi C Kanuru
NPI 1598080236
$4,171.39
in general payments reported to CMS, 2019-2025
30 companies · $2,166 in 2025
The $2,166 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $863 · 2020: $250 · 2023: $285 · 2024: $608 · 2025: $2,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,699 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $250 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,699.48 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $250.00 |
| Education | $109.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,066.32 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $538.96 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Olympus America INC. | $373.17 | 2025 | Disposable Emr Kit, Disposable Biopsy Forceps, Visiglide |
| Janssen Biotech, INC. | $342.63 | 2024-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $321.05 | 2019-2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $200.21 | 2023-2025 | Dupixent |
| Ardelyx, INC. | $186.82 | 2024-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $157.76 | 2025 | Rezdiffra |
| Shionogi INC | $122.35 | 2019 | |
| Ironwood Pharmaceuticals, INC | $119.32 | 2023-2025 | Linzess |
| Qol Medical, LLC | $88.51 | 2024-2025 | Sucraid, Sucraid |
| Amag Pharmaceuticals, INC. | $76.56 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $71.01 | 2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $66.92 | 2024-2025 | Vowst |
| Boston Scientific Corporation | $56.95 | 2023 | Superion Indirect Decompression System |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $49.92 | 2019-2020 | |
| Lilly USA, LLC | $44.72 | 2024-2025 | Omvoh |
| Genzyme Corporation | $44.71 | 2025 | |
| Daiichi Sankyo INC. | $40.08 | 2020 | |
| Merck Sharp & Dohme LLC | $39.24 | 2019-2024 | Dificid, Zerbaxa |
| Pharming Healthcare, INC. | $34.57 | 2023 | Ruconest |
| Alfasigma USA, INC. | $18.56 | 2020 | |
| Braintree Laboratories, INC. | $18.38 | 2019 | |
| Ucb, INC. | $15.93 | 2019 | |
| Pfizer INC. | $15.63 | 2020 | |
| Capsovision, INC. | $15.29 | 2025 | Capsocam Plus |
| Cook Medical LLC | $13.26 | 2019 | |
| Shire North American Group INC | $11.83 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 | |
| Echosens North America, INC. | $10.25 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reshi Kanuru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.